How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 61.2 | 61.2 | 61.6 | 52.7 | 52.7 | 52.7 | -8.4 |
| Healthcare | 26.0 | 26.0 | 25.3 | 29.7 | 29.7 | 29.7 | +3.8 |
| Chemicals | 6.4 | 6.4 | 6.8 | 7.6 | 7.6 | 7.6 | +1.2 |
| Unclassified | 2.7 | 2.7 | 2.5 | 2.9 | 2.9 | 2.9 | +0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 10.61% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| DIVISLAB | Pharma | 7.56% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| APOLLOHOSP | Healthcare | 6.63% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| TORNTPHARM | Pharma | 6.51% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| NEULANDLAB | Healthcare | 5.49% | 10 | 10 | 5 | 10 | 2 | 1/2 | +27.4% |
| NAVINFLUOR | Chemicals | 5.38% | 9 | 10 | 3 | 9 | 1 | 0/2 | +21.1% |
| AUROPHARMA | Pharma | 4.98% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| FORTIS | Healthcare | 4.49% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| GLAND | Pharma | 3.55% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| ZYDUSLIFE | Pharma | 3.15% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| ONESOURCE | Healthcare | 3.08% | 3 | 1 | 5 | 7 | 8 | 0/2 | +9.7% |
| ASTERDM | Healthcare | 3.07% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| GLENMARK | Pharma | 3.07% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| BIOCON | Pharma | 3.06% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| MEDANTA | Healthcare | 2.97% | 9 | 9 | 6 | 8 | 2 | 0/2 | +23.2% |
| IPCALAB | Pharma | 2.85% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| MANKIND | Pharma | 2.29% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| ACUTAAS | Chemicals | 2.22% | 8 | 10 | 2 | 5 | 1 | 0/2 | +43.1% |
| ANTHEM | Pharma | 2.16% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| MAXHEALTH | Healthcare | 1.82% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
Performance · 2.9y
Over the last 2.9 years ₹100 in the fund grew to ₹171 (+71%), vs ₹134 for Nifty 500 (+34%) and ₹121 for Nifty 50 (+21%). Its relative-strength line ended at 141 vs Nifty 50 and 127 vs Nifty 500 — above 100, sustained outperformance.